People_

Dr Ben Kong

Oncology Clinical Research Fellow
NHMRC Clinical Trials Centre
Faculty of Medicine and Health

Websites

Dr Ben Kong is an Oncology Research Fellow at the NHMRC Clinical Trials Centre. He is a Medical Oncologist and Staff Specialist at Royal North Shore Hospital with subspecialty interests in neuro-oncology, lung cancer and genitourinary cancers.

Research interests

Clinical trials, neuro-oncology, immunology

Awards and honours

2017 Sydney Catalyst Top-up Scholarship

2016 Australian Postgraduate Award, University of Sydney Merit Award

Themes

Cancer

Keywords

Brain tumours, Cancer, Immunology

Approaches

Clinical Trials, Immunology

Clinical speciality

Oncology

Publications

By Type

Expand all

Journals

Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]
Agar, M., Nowak, A., Hovey, E., Barnes, E., Simes, R., Vardy, J., Wheeler, H., Kong, B., Leonard, R., Hall, M., Tim, E., Spyridopoulos, D., Sim, H., et al (2023). Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. BMJ Supportive and Palliative Care, 13(3), 354-362. [More Information]
Wei, J., Yuile, A., Itchins, M., Kong, B., Li, B., Pavlakis, N., Chan, D., Clarke, S. (2023). Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines, 11(7). [More Information]
Trinder, S., McKay, C., Power, P., Topp, M., Chan, B., Valvi, S., McCowage, G., Govender, D., Kirby, M., Ziegler, D., Kellie, S., Sim, H., Kong, B., et al (2023). BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. Frontiers in Oncology, 13. [More Information]
Sim, H., Wachsmuth, L., Barnes, E., Yip, S., Koh, E., Hall, M., Jennens, R., Kong, B., Simes, R., Khasraw, M., et al (2023). NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances, 5(1), vdad124. [More Information]
Kong, B., Carter, C., Nowak, A., Hovey, E., Lwin, Z., Haghighi, N., Gan, H., Sim, H., Ziegler, D., Barton, K., Parkinson, J., Leonard, R., Khasraw, M., Foote, M. (2022). Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. Asia-Pacific Journal of Clinical Oncology, 18(3), 259-266. [More Information]
Halkett, G., Breen, L., Berg, M., Sampson, R., Sim, H., Gan, H., Kong, B., Nowak, A., Day, B., Harrup, R., et al (2022). Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers. Current Oncology, 29(12), 9928-9955. [More Information]
Kong, B., Sim, H., Barnes, E., Nowak, A., Hovey, E., Jeffree, R., Harrup, R., Parkinson, J., Gan, H., Pinkham, M., Yip, S., Hall, M., Tu, E., Carter, C., Simes, R., et al (2022). Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma. BMJ Open, 12(9). [More Information]
Kong, B., Sim, H., Nowak, A., Yip, S., Barnes, E., Day, B., Buckland, M., Verhaak, R., Johns, T., Robinson, C., Hall, M., Tu, E., et al (2021). LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open, 11(12), e054075. [More Information]
Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Eade, T., Hruby, G., Lamoury, G., Carroll, S., Morgia, M., Kneebone, A., Stevens, M., Molloy, M., Kong, B., Back, M., et al (2021). The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy? Cancers, 13(19), 4824. [More Information]
Fromm, P., Silveira, P., Hsu, J., Papadimitrious, M., Lo, T., Ju, X., Kupresanin, F., Romano, A., Hsu, W., Bryant, C., Kong, B., Abadir, E., McGuire, H., Fazekas de St Groth, B., Hart, D., Clark, G., et al (2020). Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics. Journal of Leukocyte Biology, 107(2), 323-339. [More Information]
Bryant, C., Sutherland, S., Kong, B., Papadimitrious, M., Fromm, P., Hart, D. (2019). Dendritic cells as cancer therapeutics. Seminars in Cell & Developmental Biology, 86, 77-88. [More Information]
Kong, B., Bolton, H., Kim, J., Silveira, P., Fromm, P., Clark, G. (2019). On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Frontiers in Oncology, 9, 1-13. [More Information]
Hsu, J., Bryant, C., Papadimitrious, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology, 7(4), e1419114-1-e1419114-11. [More Information]
Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Guminski, A., Long, G., Carlino, M., et al (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 116(8), 1-1. [More Information]
Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
Kong, B., Micklethwaite, K., Swaminathan, S., Kefford, R., Carlino, M. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 26(2), 202-204. [More Information]
Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
Clarke, R., Apell, H., Kong, B. (2007). Allosteric effect of ATP on Na+,K+-ATPase conformational kinetics. Biochemistry, 46(23), 7034-7044. [More Information]
Buhagiar, K., Hansen, P., Kong, B., Clarke, R., Fernandes, C., Rasmussen, H. (2004). Dietary Cholesterol Alters Na+/K+ Selectivity At Intracellular Na+/K+ Pump Sites In Cardiac Myocytes. American Journal of Physiology: Cell Physiology, 286(2), C398-C405.
Kong, B., Clarke, R. (2004). Identification Of Potential Regulatory Sites Of The Na+,K+-Atpase By Kinetic Analysis. Biochemistry, 43(8), 2241-2250. [More Information]
Hansen, P., Buhagiar, K., Kong, B., Clarke, R., Gray, D., Rasmussen, H. (2002). Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes. American Journal of Physiology: Cell Physiology, 283(5), 1511-1521. [More Information]

show 20 more

By Year

Expand all

2024

Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]

2023

Agar, M., Nowak, A., Hovey, E., Barnes, E., Simes, R., Vardy, J., Wheeler, H., Kong, B., Leonard, R., Hall, M., Tim, E., Spyridopoulos, D., Sim, H., et al (2023). Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. BMJ Supportive and Palliative Care, 13(3), 354-362. [More Information]
Wei, J., Yuile, A., Itchins, M., Kong, B., Li, B., Pavlakis, N., Chan, D., Clarke, S. (2023). Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines, 11(7). [More Information]
Trinder, S., McKay, C., Power, P., Topp, M., Chan, B., Valvi, S., McCowage, G., Govender, D., Kirby, M., Ziegler, D., Kellie, S., Sim, H., Kong, B., et al (2023). BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. Frontiers in Oncology, 13. [More Information]
Sim, H., Wachsmuth, L., Barnes, E., Yip, S., Koh, E., Hall, M., Jennens, R., Kong, B., Simes, R., Khasraw, M., et al (2023). NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances, 5(1), vdad124. [More Information]

show 1 more

2022

Kong, B., Carter, C., Nowak, A., Hovey, E., Lwin, Z., Haghighi, N., Gan, H., Sim, H., Ziegler, D., Barton, K., Parkinson, J., Leonard, R., Khasraw, M., Foote, M. (2022). Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. Asia-Pacific Journal of Clinical Oncology, 18(3), 259-266. [More Information]
Halkett, G., Breen, L., Berg, M., Sampson, R., Sim, H., Gan, H., Kong, B., Nowak, A., Day, B., Harrup, R., et al (2022). Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers. Current Oncology, 29(12), 9928-9955. [More Information]
Kong, B., Sim, H., Barnes, E., Nowak, A., Hovey, E., Jeffree, R., Harrup, R., Parkinson, J., Gan, H., Pinkham, M., Yip, S., Hall, M., Tu, E., Carter, C., Simes, R., et al (2022). Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma. BMJ Open, 12(9). [More Information]

2021

Kong, B., Sim, H., Nowak, A., Yip, S., Barnes, E., Day, B., Buckland, M., Verhaak, R., Johns, T., Robinson, C., Hall, M., Tu, E., et al (2021). LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open, 11(12), e054075. [More Information]
Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Eade, T., Hruby, G., Lamoury, G., Carroll, S., Morgia, M., Kneebone, A., Stevens, M., Molloy, M., Kong, B., Back, M., et al (2021). The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy? Cancers, 13(19), 4824. [More Information]

2020

Fromm, P., Silveira, P., Hsu, J., Papadimitrious, M., Lo, T., Ju, X., Kupresanin, F., Romano, A., Hsu, W., Bryant, C., Kong, B., Abadir, E., McGuire, H., Fazekas de St Groth, B., Hart, D., Clark, G., et al (2020). Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics. Journal of Leukocyte Biology, 107(2), 323-339. [More Information]

2019

Bryant, C., Sutherland, S., Kong, B., Papadimitrious, M., Fromm, P., Hart, D. (2019). Dendritic cells as cancer therapeutics. Seminars in Cell & Developmental Biology, 86, 77-88. [More Information]
Kong, B., Bolton, H., Kim, J., Silveira, P., Fromm, P., Clark, G. (2019). On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Frontiers in Oncology, 9, 1-13. [More Information]

2018

Hsu, J., Bryant, C., Papadimitrious, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology, 7(4), e1419114-1-e1419114-11. [More Information]

2017

Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Guminski, A., Long, G., Carlino, M., et al (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 116(8), 1-1. [More Information]
Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]

2016

Kong, B., Micklethwaite, K., Swaminathan, S., Kefford, R., Carlino, M. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 26(2), 202-204. [More Information]
Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]

2007

Clarke, R., Apell, H., Kong, B. (2007). Allosteric effect of ATP on Na+,K+-ATPase conformational kinetics. Biochemistry, 46(23), 7034-7044. [More Information]

2004

Buhagiar, K., Hansen, P., Kong, B., Clarke, R., Fernandes, C., Rasmussen, H. (2004). Dietary Cholesterol Alters Na+/K+ Selectivity At Intracellular Na+/K+ Pump Sites In Cardiac Myocytes. American Journal of Physiology: Cell Physiology, 286(2), C398-C405.
Kong, B., Clarke, R. (2004). Identification Of Potential Regulatory Sites Of The Na+,K+-Atpase By Kinetic Analysis. Biochemistry, 43(8), 2241-2250. [More Information]

2002

Hansen, P., Buhagiar, K., Kong, B., Clarke, R., Gray, D., Rasmussen, H. (2002). Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes. American Journal of Physiology: Cell Physiology, 283(5), 1511-1521. [More Information]

Selected Grants

2022